Status:
ACTIVE_NOT_RECRUITING
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Lead Sponsor:
Eli Lilly and Company
Collaborating Sponsors:
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Conditions:
Neuroblastoma
Eligibility:
All Genders
2-21 years
Phase:
PHASE1
Brief Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Eligibility Criteria
Inclusion
- Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.
- Participants must be able to swallow capsules.
Exclusion
- Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.
- Participants must not have untreated tumor that has spread to the brain or spinal cord.
- Participants must not have a serious active disease other than neuroblastoma.
- Participants must not have a condition affecting absorption.
- Participants must not have had prior aurora kinase inhibitor exposure.
- Participants must not have a known allergy to the study treatment.
- Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
Key Trial Info
Start Date :
June 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT04106219
Start Date
June 11 2020
End Date
August 1 2026
Last Update
July 23 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Medical Center at Mission Bay
San Francisco, California, United States, 94158
2
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
3
University of Chicago - Comer Children's Hospital
Chicago, Illinois, United States, 60637
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115